Clinical trials: gemcitabine hydrochloride
Pancreatic Cancer
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
- Trial name
- PANCREAS (NCT04683315)
- Testing
- mFOLFIRINOX Treatment Regimen, Gemcitabine/Nab-paclitaxel Treatment Regimen
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- Medical College of Wisconsin
Non-small Cell Lung Cancer Metastatic
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
In recent years, immunotherapy research has made great progress, especially the immunocheckpoint inhibitors represented by anti-pd-1 antibody have shown good efficacy in the treatment of malignant tumors, and some patients can…
- Trial name
- NCT04331626
- Testing
- Gemcitabine Injectable Product
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Bladder Cancer, Renal Pelvis Cancer
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
The purpose of this study is to test the safety of gemcitabine and cisplatin plus Everolimus (also called RAD001) at different dose levels.
- Conditions
- Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
- Trial name
- NCT01182168
- Testing
- gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00448838
- Testing
- Cetuximab, Gemcitabine Hydrochloride, Oxaliplatin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Miami
Hepatocellular Carcinoma, Biliary Tract Cancer
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally…
- Trial name
- NCT05733598
- Testing
- RP2, Bevacizumab, Atezolizumab
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Replimune, Inc.
Advanced or Metastatic Pancreatic Adenocarcinoma
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
A dose finding study in locally advanced and/or metastatic pancreatic cancer patients
- Trial name
- NCT00560963
- Testing
- everolimus
- Where
- 5 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068432
- Testing
- Celecoxib, Gemcitabine Hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma Metastatic, Biliary Tract Cancer
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial
- Conditions
- Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract, Adenocarinoma Locally Advanced
- Trial name
- NIFE (NCT03044587)
- Testing
- Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B)
- Where
- Germany
- Volunteers
- 93 people
- Sponsor
- AIO-Studien-gGmbH
Carcinoma, Non-Small-Cell Lung
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
Patients presenting a deterioration of the general state (performance status [PS] 2-3), constitute a population which needs an adapted treatment.
- Trial name
- NCT00198393
- Testing
- Gefitinib, gemcitabine, Docetaxel
- Where
- 2 sites in France
- Volunteers
- 126 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Carcinoma, Non Small Cell Lung
Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer
To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer
- Trial name
- NCT00191230
- Testing
- gemcitabine, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer Metastatic
A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
This is a single-center, prospective, two cohort study to evaluate the efficacy and safety of surufatinib in combination with AG or AG alone in the first-line treatment of patients with locally advanced or metastatic pancreatic…
- Trial name
- NCT05969171
- Testing
- Surufatinib, gemcitabine, nab-paclitaxel, Nab-paclitaxel, gemcitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Cholangiocarcinoma, Biliary Tract Cancer
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
The purpose of this study is to build on the efficacy of the GEMOX regimen by adding Sorafenib in the treatment of Biliary Tract Cancer.
- Conditions
- Cholangiocarcinoma, Biliary Tract Cancer, Gallbladder Cancer
- Trial name
- NCT00955721
- Testing
- Gemcitabine, Oxaliplatin, Sorafenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Pancreatic Cancer
AS703569 and Gemcitabine Combination in Advanced Malignancies
In clinical practice and research, combination of anticancer agents is often used to improve efficacy of treatment. In vitro and in vivo experiments have shown additive-synergistic anti-tumour effects of AS703569 treatment when…
- Trial name
- NCT01097512
- Testing
- AS703569/gemcitabine
- Where
- 3 sites in Belgium, France
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055887
- Testing
- carboplatin, cisplatin, efaproxiral
- Where
- 22 sites in United States, Belgium and 2 more
- Sponsor
- Spectrum Pharmaceuticals, Inc
Nasopharyngeal Carcinoma
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
A phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based…
- Trial name
- NCT06118333
- Testing
- BL-B01D1, capecitabine, gemcitabine
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors, Breast Cancer
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended…
- Trial name
- NCT06775236
- Testing
- SYS6010 jnjection, monotherapy chemotherapy, SYH2051 tablets
- Volunteers
- 410 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Neoplasm Malignant
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
Primary Objective: To assess the safety and the maximum tolerated dose(MTD) of iniparib as a single agent and in combination with chemotherapeutic regimens in patients with advanced solid tumors that are refractory to standard…
- Trial name
- NCT01455532
- Testing
- Iniparib (SAR240550-BSI-201), Gemcitabine, Carboplatin
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanofi
Adenocarcinoma of the Pancreas
Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas
The investigators' long-term goal is to improve the survival of patients with pancreatic cancer by enhancing the efficacy of gemcitabine-radiation by adding the Wee1 inhibitor MK-1775.
- Trial name
- NCT02037230
- Testing
- MK-1775, Gemcitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
Pancreatic Cancer
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00365144
- Testing
- bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.